Work Here?
Character Bio
Work Here?
Biopharmaceutical R&D using genetics-driven aging therapies
Character Bio
Work Here?
Biopharmaceutical R&D using genetics-driven aging therapies
Overview
Clover Therapeutics focuses on developing medicines for aging-related diseases by integrating genetic data with longitudinal clinical records. It does this by forming multidisciplinary partnerships to collect and analyze clinical data, then using these insights to accelerate the creation of targeted medicines designed to treat specific aging-related conditions. The company differentiates itself through its data-driven collaboration model that combines genetics, clinical data, and healthcare workflow, including partnerships with biopharmaceuticals and its affiliation with Clover Health to curate valuable data. Its goal is to make clinical research a rigorous, ethical, and seamless part of healthcare, ultimately improving patient outcomes by delivering targeted therapies for aging-related diseases.
About Character Bio
Industries
Data & Analytics
Biotechnology
Healthcare
Company Size
11-50
Company Stage
Series B
Total Funding
$151.5M
Headquarters
Clifton, New Jersey
Founded
2019
Simplify's Take
What believers are saying
- Genentech partnership validates platform and accelerates ocular therapy development.
- Clover Health affiliation provides proprietary clinical data for targeted medicines.
- Expert leadership enhances success in polygenic aging disease drug discovery.
What critics are saying
- Rebranded Character Biosciences raised $93M Series B, outpacing Clover's $1M revenue.
- Genentech terminates collaboration after data access, sidelining Clover in 18-36 months.
- 1-employee scale risks Clover Health shutdown amid cash burn in 12-24 months.
What makes Character Bio unique
- Leverages Clover Health's longitudinal patient data for genetic subgroup identification.
- Collaborates with Genentech on age-related eye diseases like dry AMD.
- Led by Cheng Zhang from Pfizer and Marcel van der Brug from Genentech.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$151.5M
Above
Industry Average
Funded Over
5 Rounds
Industry standards
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 2%2 year growth
↑ 0%Character Biosciences has filed a notice with the SEC for an exempt offering to raise $19.65 million in new funding. This filing is required under federal securities law for companies selling securities without registration under certain exemptions.
Character Biosciences enhances its leadership team and secures $93 million in Series B funding to advance treatments for degenerative eye diseases.
Character Biosciences, a precision medicine company, announced an expansion of its Series B financing with an additional $17 million.
Character Biosciences announced the expansion of its leadership team with four senior appointments and an extension of its Series B financing, raising total capital to over $110 million. The funding, with participation from Sanofi Ventures and others, will advance the clinical development of CTX114 and CTX203 for geographic atrophy and age-related macular degeneration. New executives include Robert Kim, M.D., MBA as CMO, and Daniel Elgort, Ph.D. as Chief Data & Analytics Officer.
Character Biosciences, a Jersey City, N.J.-based precision medicine company improving drug development for polygenic diseases, raised $93M in Series B funding
There are no jobs for Character Bio right now.
Find jobs on Simplify and start your career today
About Character Bio
Industries
Data & Analytics
Biotechnology
Healthcare
Company Size
11-50
Company Stage
Series B
Total Funding
$151.5M
Headquarters
Clifton, New Jersey
Founded
2019
There are no jobs for Character Bio right now.
Find jobs on Simplify and start your career today